Johnson & Johnson (JNJ) slipped 0.18% to $199.22 in afternoon trade on Tuesday, ending six-sessions of gain. Despite today's modest loss, shares remain up 3.39% over the past month, and have surged around 38% year to date,

A Los Angeles jury ordered Johnson & Johnson to pay $966 million to the family of a woman who died from mesothelioma, finding the company liable in the latest trial alleging its talc products cause cancer. The family of Mae Moore, a California resident who ...

Health care giant Johnson & Johnson (NYSE:JNJ) has had a good year with its shares trading near all-time highs. The company looks to keep a trend of beating analyst estimates when third-quarter financial results are reported before market open Tuesday.

Johnson & Johnson may be looking to deepen its relationship with immunology partner Protagonist Therapeutics with a takeover deal, The Wall Street Journal reports. The exact details of the talks aren’t yet known, but a deal would likely value Protagonist ...

Johnson & Johnson was ordered to pay $966 million to the family of a woman who alleged the New Brunswick-headquartered health giant’s talcum-based baby powder gave her a fatal cancer. Following a trial in Los Angeles Superior Court, a jury concluded Oct ...

The New York Jets have agreed to a multi-year sponsorship with Johnson & Johnson to promote better health to Jets fans, making them the team's Official Medical Innovation Sponsor. Johnson & Johnson will become the presenting sponsor of My Cause My Cleats ...

Thousands of claimants in the U.K. are suing Johnson & Johnson (NYSE:JNJ), accusing the healthcare giant of knowingly selling asbestos-contaminated talcum powder that allegedly caused cancer in consumers. The case, involving roughly 3,000 individuals, is ...

Halda Therapeutics is developing oral assets for prostate and lung cancer. The deal comes after Johnson & Johnson set an ambitious goal for its oncology sales by 2030.